cyclohexanol has been researched along with desvenlafaxine succinate in 207 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (4.83) | 18.2507 |
| 2000's | 70 (33.82) | 29.6817 |
| 2010's | 122 (58.94) | 24.3611 |
| 2020's | 5 (2.42) | 2.80 |
| Authors | Studies |
|---|---|
| Chiang, ST; Fruncillo, RJ; Parker, VD; Troy, SM | 1 |
| Blum, RA; Chiang, ST; Parker, VD; Schultz, RW; Troy, SM | 1 |
| Hicks, DR; Howell, SR; Scatina, JA; Sisenwine, SF | 1 |
| Cavanaugh, N; Hicks, DR; Kraml, M; Russell, A; Wolaniuk, D | 1 |
| Boudino, FD; Chiang, ST; Hicks, DR; Parker, VD; Troy, SM | 1 |
| Albers, L; Helmeste, D; Reist, C; Vu, RL | 1 |
| Clement, EM; Franklin, M; Odontiadis, J | 1 |
| Dusci, LJ; Groves, A; Hackett, LP; Ilett, KF; Kristensen, JH; Paech, M; Roberts, MJ; Yapp, P | 1 |
| Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W | 2 |
| Balant-Gorgia, AE; Fanali, S; Rudaz, S; Stella, C; Veuthey, JL | 1 |
| Cherkaoui, S; Rudaz, S; Veuthey, JL | 1 |
| Desiderio, C; Fanali, S; Rudaz, S; Veuthey, JL | 1 |
| Dumora, F; Jarry, C; Matoga, M; Pehourcq, F; Titier, K | 1 |
| Altshuler, L; Dunn, WA; Hendrick, V; Wertheimer, A | 1 |
| Hackett, LP; Ilett, KF; Kohan, R; Kristensen, JH; Paech, M; Rampono, J | 1 |
| Härtel, B; Kalso, E; Tasmuth, T | 1 |
| Kazimi, S; Sena, SF; Wu, AH | 1 |
| Bengtsson, F; Björk, H; Lundmark, J; Reis, M | 1 |
| Balant, LP; Balant-Gorgia, AE; Bertschy, G; Brachet, A; Gex-Fabry, M; Rudaz, S; Veuthey, JL | 1 |
| Denys, D; van der Wee, N; van Megen, HJ; Westenberg, HG | 1 |
| Balant, LP; Balant-Gorgia, AE; Bertschy, G; Gex-Fabry, M; Rudaz, S; Veuthey, JL | 1 |
| Allard, P; Behnke, K; Gram, L; Hanson, M; Søgaard, J; Timdahl, K | 1 |
| Conca, A; König, P; Moll, W; Waschgler, R | 1 |
| Kootstra-Ros, JE; van Baalen-Benedek, EH; van der Weide, J | 1 |
| Bhatt, J; Jangid, A; Singh, S; Subbaiah, G; Venkatesh, G | 1 |
| Lambert, WE; Maudens, KE; Van Peteghem, CH; Wille, SM | 1 |
| Almarza, E; Ballesteros, S; Martínez, MA | 1 |
| Begley, AE; Kirshne, MA; Mulsant, BH; Pollock, BG; Reynolds, CF; Romkes, M; Whyte, EM | 1 |
| Abou-Gharbia, M; Andree, TH; Beyer, CE; Bray, J; Deecher, DC; Johnston, G; Shah, S | 1 |
| Alfinito, PD; Chen, X; Deecher, DC; Huselton, C | 1 |
| Arneth, B; Dragicevic, A; Härtter, S; Hiemke, C; Kaiser, R; Lackner, K; Müller, MJ; Shams, ME | 1 |
| Alfinito, PD; Cosmi, S; Deecher, DC; Johnston, GH; Leventhal, L; Merchenthaler, I; Winneker, R | 1 |
| Li, HD; Liu, W; Wang, F | 1 |
| Swart, KJ; Theron, HB; van der Merwe, MJ; van der Westhuizen, JH | 1 |
| DeMartinis, NA; Entsuah, R; Manley, AL; Yeung, PP | 1 |
| Amore, M; Cesta, R; Fanali, S; Mandrioli, R; Mercolini, L; Raggi, MA | 1 |
| Blakely, RD; Deecher, DC; Mahaney, PE; Mason, JN; Richmond, RL; Stack, G; Trybulski, E; Winneker, RC | 1 |
| Bertilsson, L; Hynninen, VV; Kurkinen, K; Laine, K; Neuvonen, PJ; Olkkola, KT | 1 |
| Demeter, CA; Findling, RL; Greenhill, LL; Kotler, LA; McNamara, NK; Myers, C; O'Riordan, MA; Reed, MD | 1 |
| Panay, N | 1 |
| Germain, JM; Padmanabhan, SK; Pitrosky, B; Septien-Velez, L; Tourian, KA | 1 |
| Entsuah, R; Liebowitz, MR; Yeung, PP | 1 |
| Constantine, G; Gass, M; Olivier, S; Speroff, L | 1 |
| Fosaas, K; Hendset, M; Hermann, M; Hjerpset, M; Refsum, H | 1 |
| Patel, BN; Sanyal, M; Sharma, N; Shrivastav, PS | 1 |
| Devarakonda, S; Ram, T; Sreekanth, BR; Venu, N | 1 |
| Ganguly, R; Liebowitz, MR; Manley, AL; Padmanabhan, SK; Tourian, KA; Tummala, R | 1 |
| Brisard, C; Germain, JM; Lieberman, DZ; Montgomery, SA; Padmanabhan, K; Pitrosky, B; Rosas, G; Tourian, KA | 1 |
| Preskorn, SH | 2 |
| Lohoff, FW; Rickels, K | 1 |
| Ehret, MJ; Grgas, M; Sopko, MA | 1 |
| Hazra, M; Pollock, BG; Sproule, BA | 1 |
| Burczynski, ME; Connolly, SM; Fatato, P; Guico-Pabia, C; Isler, JA; Jiang, Q; Nichols, AI; Patroneva, A; Paul, J; Pedersen, R | 1 |
| Plosker, GL; Yang, LP | 1 |
| Ahmed, S; Fatato, P; Isler, JA; Jiang, Q; Nichols, AI; Patroneva, A; Paul, J; Pedersen, RD; Shenouda, M | 1 |
| Guico-Pabia, CJ; Helzner, EC; Nichols, AI; Patroneva, AL; Paul, J; Preskorn, SH | 1 |
| Handratta, V; Kamath, J | 1 |
| Archer, DF; Constantine, GD; Olivier, S; Pickar, JH; Seidman, L | 1 |
| Han, C; Marks, DM; Masand, PS; Pae, CU; Park, MH; Patkar, AA | 1 |
| Ahmed, S; Burczynski, ME; Isler, JA; Jiang, Q; Nichols, AI; Patroneva, A; Paul, J; Preskorn, S; Silman, H | 1 |
| Carrillo, F; Johnson, J; Laustsen, G; Smith, C | 1 |
| Archer, DF; Constantine, GD; Dupont, CM; Olivier, S; Pickar, JH | 1 |
| Hollander, E | 1 |
| Feiger, AD; Padmanabhan, SK; Rosas, GR; Tourian, KA | 1 |
| Pae, CU | 2 |
| Kumar, IJ; Rajasekhar, D; Venkateswarlu, P | 1 |
| Hussar, DA | 1 |
| Guico-Pabia, CJ; Lobello, K; Nichols, AI; Paul, J; Preskorn, SH | 1 |
| Glover, BA; Knight, BT; Newport, DJ; Ritchie, JC; Stowe, ZN; Zach, EB | 1 |
| Azam, F; Kao, J; Leung, L; Oganesian, A; Shilling, AD; Tran, J; Watanyar, A; Young-Sciame, R | 1 |
| Cassagnol, M; Perry, R | 1 |
| Brisard, C; Farrington, D; Groark, J; Padmanabhan, SK; Tourian, KA | 1 |
| Fava, M; Jiang, Q; Kornstein, SG; Tourian, KA | 1 |
| Fava, M; Guico-Pabia, CJ; Montgomery, SA; Padmanabhan, SK; Tourian, KA | 1 |
| Parabia, MH; Shah, GR; Surati, KR; Thaker, BT | 1 |
| Lilue, M; Palacios, S | 1 |
| Guico-Pabia, CJ; Jiang, Q; Kornstein, SG; Soares, CN; Thase, ME | 1 |
| Guico-Pabia, CJ; Kane, C; Musgnung, J; Ninan, PT; Pitrosky, B; Reddy, S | 1 |
| Brisard, C; Germain, JM; Guelfi, JD; Leurent, C; Montgomery, SA; Padmanabhan, SK; Pitrosky, B; Rickels, K; Tourian, KA | 1 |
| Kahn, DA; Kalia, R; Khan, AY; Magsalin, RM | 1 |
| Masand, PS; Pae, CU; Patkar, AA; Seo, HJ; Sohi, MS | 1 |
| Li, F; Li, N; Qin, F; Qin, T; Zhang, Y | 1 |
| Archer, DF | 1 |
| Feinberg, SS | 1 |
| Jiang, Q; Ninan, PT; Tourian, KA | 1 |
| Launiainen, T; Ojanperä, I; Rasanen, I; Vuori, E | 1 |
| Ahlner, J; Bengtsson, F; Carlsson, B; Josefsson, M; Karlsson, L; Kingbäck, M; Kugelberg, FC | 1 |
| Guico-Pabia, CJ; Jiang, Q; Lobello, KW; Nichols, AI; Ninan, PT; Patroneva, A; Paul, J; Preskorn, SH | 1 |
| John, J; Kandasamy, M; Ravi, S; Shekar, R; Srinivas, N; Srinivas, P; Subramaniam, K; Thangam, S | 1 |
| Clayton, AH; Guico-Pabia, CJ; Kornstein, SG; Padmanabhan, SK; Soares, CN | 1 |
| Regestein, QR | 1 |
| Clayton, A; Cohen, LS; Focht, K; Guico-Pabia, CJ; Jiang, Q; Kane, CP; Kornstein, SG; Ninan, P; Soares, CN; Thase, ME | 1 |
| Groark, J; Ninan, PT; Padmanabhan, K; Tourian, KA | 1 |
| Dolder, C; Nelson, M; Stump, A | 1 |
| Deshpande, A; Ing, A; Rizo, C; Seeman, N | 1 |
| Guico-Pabia, CJ; Jiang, Q; Kornstein, SG; Musgnung, JJ; Reddy, S | 1 |
| Bech, P; Boyer, P; Germain, JM; Haudiquet, V; Padmanabhan, K; Pitrosky, B; Tourian, KA | 1 |
| Hackett, LP; Ilett, KF; Kohan, R; Teoh, S; Watt, F | 1 |
| Hackett, LP; Ilett, KF; Kohan, R; Rampono, J; Teoh, S | 1 |
| Nichols, AI; Paul, J; Tourian, KA; Tse, SY | 1 |
| Brotchie, HL; Hyett, M; Parker, GB | 1 |
| Hasselstrøm, J | 1 |
| Behrle, JA; McGrory, SB; Nichols, AI; Paul, J; Posener, JA; Richards, LS | 1 |
| Focht, K; Jiang, Q; Kane, CP; Nichols, AI; Preskorn, SH | 1 |
| Clayton, A; Focht, K; Guico-Pabia, CJ; Jiang, Q; Kane, CP; Kornstein, SG; Ninan, PT; Soares, CN; Thase, ME | 1 |
| Fulda, S; Himmerich, H; Plümäkers, B; Rink, L; Sheldrick, AJ | 1 |
| Bachmeier, CJ; Beaulieu-Abdelahad, D; Ganey, NJ; Levin, GM; Mullan, MJ | 1 |
| Brahm, NC; Kelly-Rehm, MC | 1 |
| Chen, JD; Dai, F; Lei, Y | 1 |
| Guico-Pabia, CJ; Jiang, Q; Ninan, PT; Thase, ME | 1 |
| Kovatsi, L; Nazyropoulou, C; Samanidou, V | 1 |
| Ahlner, J; Bengtsson, F; Carlsson, B; Josefsson, M; Karlsson, L; Kingbäck, M; Kugelberg, FC; Zackrisson, AL | 1 |
| Dunlop, BW; Focht, K; Guico-Pabia, CJ; Lubaczewski, S; Reddy, S; Yang, L | 1 |
| Püttmann, W; Rúa-Gómez, PC | 3 |
| Gai, Y; Hou, J; Jiang, WL; Li, YX; Meng, Q; Tian, JW; Xing, Y; Zhong, Y; Zhu, HB | 1 |
| Fayyad, RS; Guico-Pabia, CJ; Soares, CN | 2 |
| Astl, D; Ausmanas, MK; Cheng, RF; Gallagher, JC; Seljan, P; Strzinek, RA | 1 |
| Bao, W; Bouchard, P; Cheng, RJ; Constantine, G; de Villiers, TJ; Panay, N; Vincendon, P | 1 |
| Capron, A; Classen, JF; Hantson, P; Haufroid, V; Marchandise, S; Vinetti, M | 1 |
| Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H | 1 |
| Chong, CR; Horowitz, JD; Neil, CJ; Nguyen, TH | 1 |
| Guttuso, T | 1 |
| Deckert, J; Greiner, C; Haen, E; Hiemke, C; Jabs, B; Pfuhlmann, B; Unterecker, S | 1 |
| Elhanany, S; Gasser, G; Gelman, F; Gun, J; Lev, O; Pankratov, I; Werner, P | 1 |
| Bech, P; Lunde, M; Martiny, K; Plenge, P | 1 |
| Archer, DF; Bao, W; Cheng, RJ; Constantine, G; Dupont, C; Pickar, JH; Racketa, J | 1 |
| Rowland, JT; Stephens, M; Zand Irani, A | 1 |
| Schwartz, TL | 1 |
| Ferguson, JM; Rosas, GR; Tourian, KA | 1 |
| Canny, LM; Coleman, KA; Meaney, JV; Palmer, TL; Radalj, LM; Xavier, VY | 1 |
| Clayton, AH; Fayyad, R; Focht, K; Musgnung, J; Reddy, S | 1 |
| Cheng, RF; Constantine, G; Hwang, E; Pinkerton, JV | 1 |
| Barbui, C; Cipriani, A; Furukawa, TA; Koesters, M; Nosè, M; Omori, IM; Purgato, M; Trespidi, C | 1 |
| Ahmad, SI; Dutta, L; Khuroo, A; Mishra, S; Monif, T; Mukherjee, SK | 1 |
| Abell, M; Behrle, JA; Chen, Y; Frick, G; Madelyn, A; Nichols, AI; Paul, J | 1 |
| Blanch, B; Friend, P; Gilfillan, D; Graham, RK; Hadzi-Pavlovic, D; Manicavasagar, V; Parker, G; Paterson, A; Perich, T; Sheppard, E; Synnott, H | 1 |
| Archer, DF; Cheng, RF; Guico-Pabia, CJ; Hwang, E; Pinkerton, JV | 2 |
| Ahlner, J; Boel, LW; Brock, B; Jornil, J; Nielsen, TS; Rosendal, I; Zackrisson, AL | 1 |
| Hwang, E; Iwata, N; Mele, L; Tourian, KA; Vialet, C | 1 |
| Bearman, P; Essick, C; King, M; Ross, JS | 1 |
| Boyer, P; Hwang, E; Rosenthal, JZ; Tourian, KA; Vialet, C | 1 |
| Bonato, PS; da Fonseca, P | 1 |
| Dziurkowska, E; Wesolowski, M | 1 |
| Hwang, E; Liebowitz, MR; Mele, L; Tourian, KA | 1 |
| Hao, Y; Sun, Z; Zhang, M | 1 |
| Araújo, PV; da Silva, JC; de Oliveira, SL; de Sousa, CN; Macêdo, DS; Sampaio, LR; Silva, MC; Sousa, FC; Vasconcelos, SM; Ximenes, NC | 1 |
| Ii, Y; Tourian, K; Wang, Y | 1 |
| Baird-Bellaire, S; Behrle, JA; Nichols, AI; Parker, VD; Patat, A; Paul, J | 1 |
| Bhandary, RP; Munoli, RN; Praharaj, SK; Selvaraj, AG | 1 |
| Chen, JD; Dai, F; Lei, Y; Li, S; Song, G | 1 |
| Chen, JD; Song, J; Yin, J | 1 |
| Culpepper, L; Fayyad, RS; Guico-Pabia, CJ; Musgnung, J; Papakostas, GI | 1 |
| Bachmeier, C; Beaulieu-Abdelahad, D; Levin, GM; Mullan, M; Reed, J | 1 |
| Bao, W; Guico-Pabia, CJ; Ninan, PT; Shelton, RC | 1 |
| Bao, W; Clayton, AH; Dunlop, BW; Focht, K; Kornstein, SG; Musgnung, J; Ninan, PT; Ramey, T | 1 |
| Alderman, CP; Liew, ED | 1 |
| Fawcett, JP; Gu, J; Li, Y; Sun, T; Yang, H; Yang, Y; Yang, Z; Zhang, Y; Zhao, S | 1 |
| Deckert, J; Lauer, M; Pfuhlmann, B; Proft, F; Riederer, P; Unterecker, S | 1 |
| Bao, W; Clayton, A; Guico-Pabia, CJ; Kornstein, SG | 1 |
| Berm, EJ; Brummel-Mulder, E; Hak, E; Maring, JG; Paardekooper, J; Wilffert, B | 1 |
| Cruz, DA; Javors, MA; Murrell, MD; Thompson, PM | 1 |
| Boucher, M; Endicott, J; Fayyad, RS; Guico-Pabia, CJ; Soares, CN | 1 |
| Aziz, MT; Good, BL; Lowe, DK | 1 |
| Boucher, M; Endicott, J; Fayyad, R; Guico-Pabia, C; Hsu, MA; Lam, RW | 1 |
| Chiles, D; Findling, RL; Groark, J; Ramaker, S; Tourian, KA; Yang, L | 1 |
| Jin, J; Li, X; Li, Y; Liu, W; Shao, Y; Shi, Y; Sun, F; Sun, K; Wang, A; Wang, D; Zhang, R | 1 |
| Buckley, G; Khan, A; Messig, M; Musgnung, J; Ninan, PT; Ramey, T | 1 |
| Asokan, A; Ball, AR; Hermer, L; Laird, CD; Ormerod, BK | 1 |
| Boucher, M; Kornstein, SG; McIntyre, RS; Thase, ME | 1 |
| Guo, H; Guo, W; Hartle, K; He, J; Huang, Q; Kong, J; Li, XM; Qiao, J; Wang, H; Wang, J; Zhang, H; Zhang, Y; Zhu, S | 1 |
| Newton, KM | 1 |
| Bosman, J; Larmené-Beld, KH; Smit, JP; ter Horst, PG; van der Veen, EL; Wieringa, A | 1 |
| Boucher, M; Endicott, J; Fayyad, R; Guico-Pabia, CJ; Hsu, MA; Lam, RW | 1 |
| Chen, Y; Groppi, A; Morini, L; Stramesi, C; Vignali, C | 1 |
| Berhan, A; Berhan, Y | 1 |
| Groppe, S; Gründer, G; Hiemke, C; Paulzen, M; Tauber, SC; Veselinovic, T | 1 |
| Fayyad, RS; Guico-Pabia, CJ; Kornstein, SG | 1 |
| Aga, DS; Ernstoff, AS; Love, NG; Moline, CJ; Stadler, LB; Su, L | 1 |
| Brignone, M; Ereshefsky, L; Francois, C; Lançon, C; Llorca, PM; Rive, B; Salah, S | 1 |
| Gallagher, JC; Tella, SH | 1 |
| Deckert, J; Hempel, S; Kopf, J; Olmes, D; Pfuhlmann, B; Proft, F; Reif, A; Riederer, P; Schmidt, B; Unterecker, S | 1 |
| Cheng, RF; Clayton, AH; Focht, K; Hwang, E; Thase, ME; Tourian, KA | 1 |
| Hou, J; Meng, Q; Tian, J; Wu, Y; Xing, Y; Yang, M; Zuo, D | 1 |
| Barry, M; Gilbert, K; Godbout, R; Malick, M; Rousseau, G | 1 |
| Alves, G; Falcão, A; LLerena, A; Magalhães, P; Rodrigues, M | 1 |
| Boucher, M; Cheng, RF; Fayyad, R; Guico-Pabia, CJ; Sporn, J; Thase, ME; Tourian, KA | 1 |
| Bao, W; Clayton, AH; Guico-Pabia, CJ; Kornstein, SG | 1 |
| Chen, XY; Chen, YX; Du, JB; Zhang, YF; Zhong, DF | 1 |
| Eliasson, E; Haslemo, T; Lindh, JD; Mannheimer, B; Molden, E | 1 |
| Domingues, DS; Miranda, LF; Queiroz, ME | 1 |
| Fay, B; Gründer, G; Haen, E; Hiemke, C; Paulzen, M; Schoretsanitis, G; Unholzer, S | 1 |
| Eliasson, E; Haslemo, T; Ingelman-Sundberg, M; Jukić, MM; Molden, E | 1 |
| Barabás-Hajdu, E; Budău, M; Hancu, G; Lupu, D; Milan, A | 1 |
| Domingo-Echaburu, S; Hernandez, R; Lertxundi, U; Medrano, J; Orive, G | 1 |
| Norman, TR; Olver, JS | 1 |
| Conca, A; De Donatis, D; Florio, V; Giupponi, G; Mercolini, L; Porcelli, S; Serretti, A; Zernig, G | 1 |
| Bansal, R; Chen, Y; Hellerstein, DJ; Peterson, BS; Sawardekar, S | 1 |
33 review(s) available for cyclohexanol and desvenlafaxine succinate
| Article | Year |
|---|---|
New products and regimens (since 2003).
Topics: Administration, Cutaneous; Cyclohexanols; Desvenlafaxine Succinate; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Menopause; Progestins; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators | 2007 |
A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2008 |
Desvenlafaxine succinate for the treatment of major depressive disorder.
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Humans; Selective Serotonin Reuptake Inhibitors | 2008 |
Desvenlafaxine: another "me too" drug?
Topics: Antidepressive Agents; Clinical Trials as Topic; Cyclohexanols; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Drug Costs; Drug Interactions; Humans; Remission Induction; Venlafaxine Hydrochloride | 2008 |
Desvenlafaxine succinate for major depressive disorder.
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Humans; Selective Serotonin Reuptake Inhibitors | 2008 |
Desvenlafaxine extended release.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Desvenlafaxine Succinate; Drug Administration Schedule; Humans; Neurotransmitter Uptake Inhibitors | 2008 |
Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Desipramine; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Health Status; Humans; Paroxetine; Thiophenes | 2008 |
Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.
Topics: Antidepressive Agents; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Humans | 2008 |
Desvenlafaxine: a new antidepressant or just another one?
Topics: Animals; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Humans; Nausea; Randomized Controlled Trials as Topic | 2009 |
Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Area Under Curve; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Female; Half-Life; Humans; Male; Middle Aged; Neurotransmitter Uptake Inhibitors; Pregnancy | 2009 |
[Non-hormonal treatment for vasomotor symptoms during menopause: role of desvenlafaxine].
Topics: Cyclohexanols; Desvenlafaxine Succinate; Female; Humans; Menopause; Neurotransmitter Uptake Inhibitors; Vasomotor System | 2009 |
Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Health Status; Humans; Male; Placebos; Psychometrics; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Treatment Outcome | 2009 |
Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Humans; Neurotransmitter Uptake Inhibitors; Placebos; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms.
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder; Desvenlafaxine Succinate; Humans; Neurotransmitter Uptake Inhibitors; Receptors, Adrenergic; Somatoform Disorders; Vasomotor System | 2010 |
Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials.
Topics: Adult; Antidepressive Agents; Anxiety; Clinical Trials, Phase III as Topic; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Area Under Curve; Biological Availability; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP2D6; Desvenlafaxine Succinate; Female; Genotype; Humans; India; Male; Phenotype; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Therapeutic Equivalency; Venlafaxine Hydrochloride | 2010 |
Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.
Topics: Aged; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Drug Interactions; Duloxetine Hydrochloride; Humans; Thiophenes | 2010 |
Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclohexanols; Cytochrome P-450 Enzyme System; Depressive Disorder, Major; Desvenlafaxine Succinate; Drug Interactions; Humans; Selective Serotonin Reuptake Inhibitors | 2010 |
Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis.
Topics: Adult; Antidepressive Agents; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Disability Evaluation; Emotions; Evidence-Based Medicine; Female; Humans; Linear Models; Logistic Models; Male; Middle Aged; Predictive Value of Tests; Psychiatric Status Rating Scales; Recovery of Function; Remission Induction; Severity of Illness Index; Time Factors; Treatment Outcome | 2012 |
Desvenlafaxine in the treatment of major depressive disorder.
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Effective and clinically meaningful non-hormonal hot flash therapies.
Topics: Actaea; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Cyclohexanols; Desvenlafaxine Succinate; Estrogen Replacement Therapy; Female; Gabapentin; gamma-Aminobutyric Acid; Glycine max; Hot Flashes; Humans; Isoflavones; Mandelic Acids; Menopause; Phytotherapy; Plant Extracts | 2012 |
Duloxetine versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Desvenlafaxine Succinate; Dibenzothiazepines; Duloxetine Hydrochloride; Fluoxetine; Humans; Paroxetine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Thiophenes; Venlafaxine Hydrochloride | 2012 |
Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials.
Topics: Antidepressive Agents; Cyclohexanols; Desvenlafaxine Succinate; Female; Hot Flashes; Humans; Menopause; Middle Aged; Randomized Controlled Trials as Topic | 2013 |
Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Drug Administration Schedule; Female; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2014 |
Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy.
Topics: Antineoplastic Agents; Cyclohexanols; Cyclopropanes; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Humans; Milnacipran; Neurotransmitter Uptake Inhibitors; Norepinephrine; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Serotonin; Thiophenes; Venlafaxine Hydrochloride | 2014 |
Desvenlafaxine for the treatment of major depressive disorder.
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Drug Interactions; Humans; Secondary Prevention; Selective Serotonin Reuptake Inhibitors | 2014 |
Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor symptoms? A meta-analysis and meta-regression of randomized double-blind controlled studies.
Topics: Chemotherapy, Adjuvant; Cyclohexanols; Desvenlafaxine Succinate; Double-Blind Method; Female; Hot Flashes; Humans; Menopause; Neurotransmitter Uptake Inhibitors; Randomized Controlled Trials as Topic; Regression Analysis | 2014 |
The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Humans; Randomized Controlled Trials as Topic | 2014 |
Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
Topics: Acetamides; Adult; Aged; Antidepressive Agents; Benzofurans; Citalopram; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Humans; Hypnotics and Sedatives; Indoles; Male; Middle Aged; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Sulfides; Thiophenes; Venlafaxine Hydrochloride; Vilazodone Hydrochloride; Vortioxetine | 2014 |
Efficacy of desvenlafaxine succinate for menopausal hot flashes.
Topics: Affect; Cyclohexanols; Desvenlafaxine Succinate; Female; Hot Flashes; Humans; Menopause; Quality of Life; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sleep | 2014 |
Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis.
Topics: Adult; Antidepressive Agents; Blood Pressure; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Enantioselective analysis of venlafaxine and its active metabolites: A review on the separation methodologies.
Topics: Antidepressive Agents; Chromatography, Liquid; Cyclohexanols; Desvenlafaxine Succinate; Electrophoresis, Capillary; Humans; Stereoisomerism; Tandem Mass Spectrometry; Venlafaxine Hydrochloride | 2021 |
Desvenlafaxine in the treatment of major depression: an updated overview.
Topics: Adolescent; Adult; Antidepressive Agents; Child; Cyclohexanols; Depression; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Drug Interactions; Female; Humans | 2021 |
62 trial(s) available for cyclohexanol and desvenlafaxine succinate
| Article | Year |
|---|---|
The pharmacokinetics of venlafaxine when given in a twice-daily regimen.
Topics: Adult; Antidepressive Agents, Second-Generation; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Cyclohexanols; Desvenlafaxine Succinate; Drug Administration Schedule; Female; Humans; Male; Venlafaxine Hydrochloride | 1995 |
Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium.
Topics: Administration, Oral; Adolescent; Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Desvenlafaxine Succinate; Drug Administration Schedule; Drug Interactions; Humans; Lithium; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1996 |
Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk.
Topics: Adult; Antidepressive Agents; Area Under Curve; Breast Feeding; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Female; Humans; Infant; Infant, Newborn; Milk, Human; Tissue Distribution; Venlafaxine Hydrochloride | 1998 |
Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine.
Topics: Adult; Antidepressive Agents, Second-Generation; Area Under Curve; Caffeine; Central Nervous System Stimulants; Cyclohexanols; Cytochrome P-450 CYP1A2; Desvenlafaxine Succinate; Drug Interactions; Female; Humans; Male; Patient Dropouts; Time Factors; Venlafaxine Hydrochloride | 1999 |
Venlafaxine in neuropathic pain following treatment of breast cancer.
Topics: Analgesics; Breast Neoplasms; Cross-Over Studies; Cyclohexanols; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Female; Humans; Mastectomy; Neuralgia; Pain Measurement; Peripheral Nervous System Diseases; Postoperative Complications; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability.
Topics: Adult; Age Factors; Antidepressive Agents, Second-Generation; Cyclohexanols; Desvenlafaxine Succinate; Drug Interactions; Female; Humans; Male; Middle Aged; Sex Factors; Stereoisomerism; Structure-Activity Relationship; Venlafaxine Hydrochloride | 2002 |
A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Cyclohexanols; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Patient Dropouts; Psychological Tests; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2003 |
Time course of clinical response to venlafaxine: relevance of plasma level and chirality.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Desvenlafaxine Succinate; Female; Humans; Male; Middle Aged; Severity of Illness Index; Stereoisomerism; Venlafaxine Hydrochloride | 2004 |
Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Body Weight; Citalopram; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Severity of Illness Index; Venlafaxine Hydrochloride | 2004 |
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Cytochrome P-450 CYP2D6; Depressive Disorder; Desvenlafaxine Succinate; Female; Genotype; Humans; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Venlafaxine Hydrochloride | 2006 |
A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Remission Induction; Treatment Outcome | 2007 |
Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine.
Topics: Adult; Antidepressive Agents, Second-Generation; Area Under Curve; Biotransformation; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dealkylation; Desvenlafaxine Succinate; Drug Interactions; Enzyme Inhibitors; Genotype; Half-Life; Humans; Male; Naphthalenes; Phenotype; Polymorphism, Genetic; Pyrimidines; Reference Values; Terbinafine; Triazoles; Venlafaxine Hydrochloride; Voriconazole | 2008 |
Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Cyclohexanols; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Faculty; Female; Humans; Male; Norepinephrine; Parents; Pilot Projects; Psychiatric Status Rating Scales; Psychometrics; Selective Serotonin Reuptake Inhibitors; Serotonin; Severity of Illness Index; Venlafaxine Hydrochloride | 2007 |
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Patient Dropouts; Psychiatric Status Rating Scales; Sex Factors; Sweating; Treatment Outcome | 2007 |
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Cholesterol, HDL; Cholesterol, LDL; Cyclohexanols; Demography; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Humans; Male; Remission Induction; Severity of Illness Index | 2007 |
Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
Topics: Adult; Aged; Cyclohexanols; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hot Flashes; Humans; Menopause; Middle Aged; Neurotransmitter Uptake Inhibitors; Treatment Outcome | 2008 |
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.
Topics: Adolescent; Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Outpatients; Placebos; Treatment Outcome | 2008 |
An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.
Topics: Adult; Antidepressive Agents; Area Under Curve; Biotransformation; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP2D6; Desipramine; Desvenlafaxine Succinate; Drug Interactions; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Thiophenes | 2008 |
The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults.
Topics: Adult; Antidepressive Agents; Area Under Curve; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Desipramine; Desvenlafaxine Succinate; Drug Interactions; Enzyme Inhibitors; Female; Genotype; Humans; Least-Squares Analysis; Male; Middle Aged; Paroxetine; United States; Young Adult | 2009 |
A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.
Topics: Adult; Aged; Cyclohexanols; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hot Flashes; Humans; Middle Aged; Neurotransmitter Uptake Inhibitors; Postmenopause; Treatment Outcome; United States; Vasomotor System | 2009 |
Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Topics: Adult; Antidepressive Agents, Second-Generation; Area Under Curve; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP2D6; Delayed-Action Preparations; Desvenlafaxine Succinate; Female; Genotype; Humans; Male; Middle Aged; Venlafaxine Hydrochloride; Young Adult | 2009 |
Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.
Topics: Cyclohexanols; Desvenlafaxine Succinate; Female; Hot Flashes; Humans; Menopause; Middle Aged; Neurotransmitter Uptake Inhibitors; Placebos; Severity of Illness Index; Treatment Outcome; Vasomotor System | 2009 |
A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Outpatients; Placebos; Treatment Outcome; Young Adult | 2009 |
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Neurotransmitter Uptake Inhibitors; Placebos | 2009 |
Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Psychiatric Status Rating Scales; Secondary Prevention; Treatment Outcome | 2010 |
Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Cyclohexanols; Cytochrome P-450 CYP2D6; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Male; Middle Aged; Phenotype; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2010 |
Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder.
Topics: Adult; Aged; Blood Pressure; Citalopram; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Liver Function Tests; Middle Aged; Neurotransmitter Uptake Inhibitors; Postmenopause; Selective Serotonin Reuptake Inhibitors; Sleep; Weight Gain | 2010 |
Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Menopause; Middle Aged; Postmenopause; Psychiatric Status Rating Scales; Treatment Outcome | 2010 |
The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment.
Topics: Adolescent; Adult; Aged; Area Under Curve; Cyclohexanols; Desvenlafaxine Succinate; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Neurotransmitter Uptake Inhibitors; Stereoisomerism | 2011 |
Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
Topics: Adult; Area Under Curve; Chromatography, Liquid; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP2D6; Delayed-Action Preparations; Desvenlafaxine Succinate; Female; Genotype; Humans; Male; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Tandem Mass Spectrometry; Venlafaxine Hydrochloride; Young Adult | 2011 |
Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
Topics: Adult; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Drug Resistance; Female; Humans; Middle Aged; Postmenopause; Psychiatric Status Rating Scales; Treatment Outcome | 2011 |
Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders.
Topics: Adolescent; Adult; Aged; Algorithms; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Drug Resistance; Drug Substitution; Female; Humans; Male; Middle Aged; Placebos; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2011 |
Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Employment; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outpatients; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome | 2011 |
The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause.
Topics: Aged; Cyclohexanols; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hot Flashes; Humans; Middle Aged; Nausea; Neurotransmitter Uptake Inhibitors; Patient Satisfaction; Postmenopause; Vasomotor System | 2012 |
Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
Topics: Adult; Aged; Cyclohexanols; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Estrogen Receptor Modulators; Female; Follicle Stimulating Hormone; Hot Flashes; Humans; Menopause; Middle Aged; Neurotransmitter Uptake Inhibitors; Norpregnenes; Treatment Outcome; Vasomotor System | 2012 |
Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.
Topics: Adult; Antidepressive Agents; Capsules; Cyclohexanols; Delayed-Action Preparations; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Drug Interactions; Female; Half-Life; HIV Protease Inhibitors; Humans; Indinavir; Male; Metabolic Clearance Rate; Selective Serotonin Reuptake Inhibitors; Tablets; Venlafaxine Hydrochloride; Young Adult | 2012 |
A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression.
Topics: Adult; Aged; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pindolol; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2012 |
Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms.
Topics: Adult; Affective Symptoms; Aged; Anger; Anxiety; Back Pain; Confusion; Cyclohexanols; Depression; Desvenlafaxine Succinate; Double-Blind Method; Fatigue; Female; Hot Flashes; Humans; Hyperhidrosis; Irritable Mood; Menopause; Middle Aged; Neurotransmitter Uptake Inhibitors; Patient Satisfaction; Sexual Behavior; Surveys and Questionnaires | 2013 |
High-dose desvenlafaxine in outpatients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Longitudinal Studies; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2012 |
An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Male; Prospective Studies; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Surveys and Questionnaires | 2013 |
Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
Topics: Aged; Antidepressive Agents; Cyclohexanols; Desvenlafaxine Succinate; Double-Blind Method; Female; Hot Flashes; Humans; Menopause; Middle Aged; Placebos; Postmenopause; Treatment Outcome | 2013 |
Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults.
Topics: Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Biological Availability; Cyclohexanols; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Desipramine; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Metabolic Detoxication, Phase I; Middle Aged; Neurotransmitter Uptake Inhibitors; Polymorphism, Genetic; Young Adult | 2013 |
The superiority of antidepressant medication to cognitive behavior therapy in melancholic depressed patients: a 12-week single-blind randomized study.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Cognitive Behavioral Therapy; Cyclohexanols; Depressive Disorder; Desvenlafaxine Succinate; Female; Humans; Male; Middle Aged; Pilot Projects; Single-Blind Method; Treatment Outcome | 2013 |
Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
Topics: Aged; Antidepressive Agents; Cyclohexanols; Desvenlafaxine Succinate; Double-Blind Method; Female; Hot Flashes; Humans; Menopause; Middle Aged; Placebos; Postmenopause; Treatment Outcome | 2013 |
Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause.
Topics: Aged; Cardiovascular Diseases; Cerebrovascular Disorders; Chemical and Drug Induced Liver Injury; Cyclohexanols; Desvenlafaxine Succinate; Double-Blind Method; Female; Hot Flashes; Humans; Menopause; Middle Aged; Placebos; Risk Factors; Treatment Outcome | 2013 |
Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult | 2013 |
Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial.
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2013 |
A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome | 2013 |
A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Diagnostic and Statistical Manual of Mental Disorders; Disorders of Excessive Somnolence; Drug Monitoring; Female; Headache; Humans; Incidence; Intention to Treat Analysis; Japan; Male; Middle Aged; Nasopharyngitis; Nausea; Neurotransmitter Uptake Inhibitors; Psychiatric Status Rating Scales | 2013 |
An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclohexanols; Desvenlafaxine Succinate; Female; Humans; Liver; Liver Diseases; Male; Middle Aged; Neurotransmitter Uptake Inhibitors; Young Adult | 2013 |
Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Male; Middle Aged; Placebo Effect; Severity of Illness Index; Young Adult | 2013 |
BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Topics: Adult; Aged; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cyclohexanols; Depression; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Hydrocortisone; Interleukin-6; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Saliva; Severity of Illness Index; Statistics as Topic; Young Adult | 2014 |
Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
Topics: Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Humans; Menopause; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome | 2013 |
Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
Topics: Administration, Oral; Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Menopause; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome | 2014 |
Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine.
Topics: Adult; Aged; Antidepressive Agents; Canada; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Efficiency; Employment; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Neurotransmitter Uptake Inhibitors; Psychiatric Status Rating Scales; Self Report; Severity of Illness Index; Time Factors; United States; Young Adult | 2014 |
Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder.
Topics: Adolescent; Antidepressive Agents; Child; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Female; Humans; Male; Severity of Illness Index; Suicidal Ideation; Time Factors | 2014 |
Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Drug Administration Schedule; Humans; Outpatients; Substance Withdrawal Syndrome | 2014 |
Concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during pregnancy.
Topics: Adult; Cyclohexanols; Desvenlafaxine Succinate; Female; Humans; Postpartum Period; Pregnancy; Pregnancy Outcome; Pregnancy Trimesters; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2014 |
Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder.
Topics: Adult; Aged; Antidepressive Agents; Cyclohexanols; Depression; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Employment; Female; Humans; Male; Middle Aged; Placebos; Quality of Life; Surveys and Questionnaires; Young Adult | 2014 |
SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome.
Topics: Adolescent; Adult; Aged; Alleles; Antidepressive Agents; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Female; Genotype; Humans; Male; Middle Aged; Norepinephrine Plasma Membrane Transport Proteins; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Venlafaxine Hydrochloride; Young Adult | 2014 |
Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial.
Topics: Adult; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Male; Middle Aged; Neurotransmitter Uptake Inhibitors; Sexual Dysfunction, Physiological; Treatment Outcome | 2015 |
A randomized controlled trial of desvenlafaxine-induced structural brain changes in the treatment of persistent depressive disorder.
Topics: Brain; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Humans | 2023 |
112 other study(ies) available for cyclohexanol and desvenlafaxine succinate
| Article | Year |
|---|---|
The effect of renal disease on the disposition of venlafaxine.
Topics: Analysis of Variance; Cyclohexanols; Desvenlafaxine Succinate; Female; Humans; Kidney Failure, Chronic; Male; Neurotransmitter Uptake Inhibitors; Renal Dialysis; Venlafaxine Hydrochloride | 1994 |
Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals.
Topics: Administration, Oral; Animals; Animals, Laboratory; Antihypertensive Agents; Biological Availability; Cyclohexanols; Desvenlafaxine Succinate; Dogs; Female; Injections, Intravenous; Macaca mulatta; Male; Metabolic Clearance Rate; Mice; Neurotransmitter Uptake Inhibitors; Rats; Rats, Sprague-Dawley; Species Specificity; Venlafaxine Hydrochloride | 1994 |
A high-performance liquid chromatographic method for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in biological fluids.
Topics: Animals; Antidepressive Agents; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Dogs; Half-Life; Humans; Indicators and Reagents; Mice; Rats; Spectrophotometry, Ultraviolet; Venlafaxine Hydrochloride | 1994 |
Rapid determination of venlafaxine and O-desmethylvenlafaxine in human plasma by high-performance liquid chromatography with fluorimetric detection.
Topics: Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Circadian Rhythm; Cyclohexanols; Desvenlafaxine Succinate; Humans; Linear Models; Osmolar Concentration; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Venlafaxine Hydrochloride | 1997 |
Simultaneous measurement of venlafaxine and its major metabolite, oxydesmethylvenlafaxine, in human plasma by high-performance liquid chromatography with coulometric detection and utilisation of solid-phase extraction.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Humans; Paroxetine; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Venlafaxine Hydrochloride | 1998 |
Effect of venlafaxine on the pharmacokinetics of risperidone.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety; Area Under Curve; Cyclohexanols; Desvenlafaxine Succinate; Exploratory Behavior; Female; Humans; Isoxazoles; Male; Metabolic Clearance Rate; Middle Aged; Paliperidone Palmitate; Psychomotor Performance; Pyrimidines; Risperidone; Venlafaxine Hydrochloride | 1999 |
Simultaneous stereoselective analysis of venlafaxine and O-desmethylvenlafaxine enantiomers in clinical samples by capillary electrophoresis using charged cyclodextrins.
Topics: Antidepressive Agents, Second-Generation; Cyclodextrins; Cyclohexanols; Desvenlafaxine Succinate; Electrophoresis, Capillary; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism; Venlafaxine Hydrochloride | 2000 |
Nonaqueous capillary electrophoresis-mass spectrometry for separation of venlafaxine and its phase I metabolites.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Desvenlafaxine Succinate; Electrophoresis, Capillary; Molecular Structure; Spectrometry, Mass, Electrospray Ionization; Venlafaxine Hydrochloride | 2001 |
Use of vancomycin silica stationary phase in packed capillary electrochromatography. II. Enantiomer separation of venlafaxine and O-desmethylvenlafaxine in human plasma.
Topics: Antidepressive Agents, Second-Generation; Chromatography, Micellar Electrokinetic Capillary; Cyclohexanols; Desvenlafaxine Succinate; Sensitivity and Specificity; Silicon Dioxide; Stereoisomerism; Vancomycin; Venlafaxine Hydrochloride | 2001 |
Rapid high-performance liquid chromatographic measurement of venlafaxine and O-desmethylvenlafaxine in human plasma. Application to management of acute intoxications.
Topics: Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Humans; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Venlafaxine Hydrochloride | 2001 |
Venlafaxine and breast-feeding.
Topics: Adult; Breast Feeding; Cyclohexanols; Depression, Postpartum; Desvenlafaxine Succinate; Female; Humans; Infant; Infant, Newborn; Male; Milk, Human; Venlafaxine Hydrochloride | 2001 |
Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants.
Topics: Adult; Antidepressive Agents; Area Under Curve; Breast Feeding; Confidence Intervals; Cyclohexanols; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Female; Humans; Infant; Lactation; Male; Milk, Human; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2002 |
False-positive phencyclidine immunoassay results caused by venlafaxine and O-desmethylvenlafaxine.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Cyclohexanols; Desvenlafaxine Succinate; False Positive Reactions; Female; Humans; Immunoassay; Male; Middle Aged; Phencyclidine; Venlafaxine Hydrochloride | 2002 |
Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Female; Humans; Male; Middle Aged; Sex Factors; Smoking; Stereoisomerism; Venlafaxine Hydrochloride | 2002 |
Quantification of venlafaxine and O-desmethylvenlafaxine in human serum using HPLC analysis.
Topics: Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Cost-Benefit Analysis; Cyclohexanols; Desvenlafaxine Succinate; Humans; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Time Factors; Venlafaxine Hydrochloride | 2004 |
Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
Topics: Alleles; Amitriptyline; Aryl Hydrocarbon Hydroxylases; Cyclohexanols; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Desvenlafaxine Succinate; Enzyme Activation; Gene Frequency; Genotype; Humans; Metabolic Clearance Rate; Mixed Function Oxygenases; Psychotropic Drugs; Risperidone; Venlafaxine Hydrochloride | 2005 |
Liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for simultaneous determination of venlafaxine and its active metabolite O-desmethyl venlafaxine in human plasma.
Topics: Antidepressive Agents, Second-Generation; Chromatography, Liquid; Citalopram; Cyclohexanols; Desvenlafaxine Succinate; Humans; Reference Standards; Spectrometry, Mass, Electrospray Ionization; Venlafaxine Hydrochloride | 2005 |
Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Desvenlafaxine Succinate; Fluoxetine; Gas Chromatography-Mass Spectrometry; Humans; Mianserin; Microchemistry; Mirtazapine; Piperazines; Reproducibility of Results; Sertraline | 2005 |
Anesthesiologist suicide with atracurium.
Topics: Anesthesiology; Atracurium; Central Nervous System Agents; Chromatography, Gas; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Forensic Medicine; Humans; Isoquinolines; Male; Middle Aged; Neuromuscular Depolarizing Agents; Opium; Suicide; Venlafaxine Hydrochloride | 2006 |
CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Creatinine; Cyclohexanols; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Desvenlafaxine Succinate; Female; Genotype; Humans; Male; Venlafaxine Hydrochloride | 2006 |
Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.
Topics: Adrenergic Uptake Inhibitors; Animals; Brain; Brain Chemistry; Cell Line; Cell Membrane; Cyclohexanols; Desvenlafaxine Succinate; Dopamine Plasma Membrane Transport Proteins; Humans; Hypothalamus; Male; Microdialysis; Norepinephrine Plasma Membrane Transport Proteins; Protein Binding; Radioligand Assay; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins | 2006 |
Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Brain Chemistry; Cyclohexanols; Desvenlafaxine Succinate; Dopamine; Female; Microdialysis; Norepinephrine; Ovariectomy; Preoptic Area; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Stereotaxic Techniques | 2006 |
Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Animals; Body Temperature Regulation; Cyclohexanols; Desvenlafaxine Succinate; Drug Evaluation, Preclinical; Ethinyl Estradiol; Female; Models, Animal; Morphine Dependence; Norepinephrine; Ovariectomy; Preoptic Area; Rats; Serotonin Antagonists; Telemetry | 2007 |
Simultaneous stereoselective analysis of venlafaxine and O-desmethylvenlafaxine enantiomers in human plasma by HPLC-ESI/MS using a vancomycin chiral column.
Topics: Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Stereoisomerism; Vancomycin; Venlafaxine Hydrochloride | 2007 |
Employing atmospheric pressure photoionization in liquid chromatography/tandem mass spectrometry to minimize ion suppression and matrix effects for the quantification of venlafaxine and O-desmethylvenlafaxine.
Topics: Antidepressive Agents, Second-Generation; Biotransformation; Calibration; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cyclohexanols; Desvenlafaxine Succinate; Flow Injection Analysis; Humans; Indicators and Reagents; Linear Models; Quality Control; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Venlafaxine Hydrochloride | 2007 |
Analysis of the second generation antidepressant venlafaxine and its main active metabolite O-desmethylvenlafaxine in human plasma by HPLC with spectrofluorimetric detection.
Topics: Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Venlafaxine Hydrochloride | 2007 |
Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter.
Topics: Binding Sites; Binding, Competitive; Blotting, Western; Cells, Cultured; Cocaine; Cyclohexanols; Desvenlafaxine Succinate; Fluoxetine; Humans; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Radioligand Assay | 2007 |
Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antidepressive Agents, Second-Generation; Cyclohexanols; Cytochrome P-450 CYP2D6; Desvenlafaxine Succinate; Female; Genotype; Heterozygote; Humans; Male; Middle Aged; Retrospective Studies; Venlafaxine Hydrochloride | 2008 |
Liquid chromatography tandem mass spectrometry assay for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in human plasma and its application to a bioequivalence study.
Topics: Area Under Curve; Chromatography, Liquid; Cyclohexanols; Desvenlafaxine Succinate; Drug Stability; Humans; Sensitivity and Specificity; Tandem Mass Spectrometry; Therapeutic Equivalency; Venlafaxine Hydrochloride | 2008 |
Desvenlafaxine succinate monohydrate.
Topics: Antidepressive Agents; Crystallography; Cyclohexanols; Desvenlafaxine Succinate; Hydrogen Bonding; Molecular Conformation; Solubility | 2008 |
Desvenlafaxine for depression.
Topics: Antidepressive Agents; Cyclohexanols; Depression; Depressive Disorder, Major; Desvenlafaxine Succinate; Drug Interactions; Humans; Neurotransmitter Uptake Inhibitors | 2008 |
Flat dose-response curves for efficacy: what do they mean to the clinician?
Topics: Attitude of Health Personnel; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluoxetine; Humans; Neurotransmitter Uptake Inhibitors; Paroxetine; Physicians; Randomized Controlled Trials as Topic; Sertraline; Treatment Outcome; United States; United States Food and Drug Administration | 2008 |
Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause.
Topics: Animals; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Female; Humans; Menopause; Molecular Structure; Neuralgia; Norepinephrine; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship; Vasomotor System | 2009 |
Drug approvals: '08 in review. Desvenlafaxine (Pristiq).
Topics: Cyclohexanols; Depression; Desvenlafaxine Succinate; Humans; Neurotransmitter Uptake Inhibitors | 2009 |
New technologies: the good, the bad, and the ugly.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Cyclohexanols; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Desvenlafaxine Succinate; Gene Expression Profiling; Humans; Oligonucleotide Array Sequence Analysis | 2009 |
Rapid high-performance liquid chromatography-tandem mass spectrometry method for simultaneous measurement of venlafaxine and O-desmethylvenlafaxine in human plasma and its application in comparative bioavailability study.
Topics: Biological Availability; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Humans; Limit of Detection; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Tandem Mass Spectrometry; Venlafaxine Hydrochloride | 2009 |
New drug update: 2008.
Topics: Animals; Anti-Allergic Agents; Antidepressive Agents; Antihypertensive Agents; Benzopyrans; Cyclohexanols; Desvenlafaxine Succinate; Ethanolamines; Humans; Naltrexone; Narcotic Antagonists; Nebivolol; Pregnenediones; Quaternary Ammonium Compounds | 2009 |
Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
Topics: Administration, Oral; Adolescent; Adrenergic Uptake Inhibitors; Adult; Biotransformation; Clinical Trials as Topic; Cyclohexanols; Cytochrome P-450 CYP2D6; Desvenlafaxine Succinate; Female; Genotype; Humans; Male; Middle Aged; Phenotype; Predictive Value of Tests; Selective Serotonin Reuptake Inhibitors; Substrate Specificity; Venlafaxine Hydrochloride; Young Adult | 2009 |
Venlafaxine in human breast milk and nursing infant plasma: determination of exposure.
Topics: Adult; Breast Feeding; Chromatography, High Pressure Liquid; Cyclohexanols; Delayed-Action Preparations; Desvenlafaxine Succinate; Female; Humans; Infant; Infant, Newborn; Lactation; Milk, Human; Neurotransmitter Uptake Inhibitors; Pregnancy; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2009 |
Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.
Topics: Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cyclohexanols; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Desvenlafaxine Succinate; Drug Interactions; Humans; In Vitro Techniques; Inhibitory Concentration 50; Microsomes, Liver; Venlafaxine Hydrochloride | 2009 |
Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome | 2009 |
Simultaneous determination of venlafaxine and its main active metabolite O-desmethyl venlafaxine in rat plasma by LC-MS/MS.
Topics: Animals; Blood Chemical Analysis; Calibration; Carbamazepine; Chromatography, Liquid; Cyclohexanols; Desvenlafaxine Succinate; Limit of Detection; Linear Models; Male; Rats; Rats, Sprague-Dawley; Reference Standards; Solid Phase Extraction; Solvents; Tandem Mass Spectrometry; Time Factors; Venlafaxine Hydrochloride | 2009 |
Desvenlafaxine: application withdrawal. Desvenlafaxine: withdrawal of marketing application for depression also.
Topics: Antidepressive Agents; Cyclohexanols; Depression; Depressive Disorder; Desvenlafaxine Succinate; Europe; Hot Flashes; Humans; Investigational New Drug Application; Marketing of Health Services; Neurotransmitter Uptake Inhibitors; Postmenopause; United States | 2009 |
Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Cytochrome P-450 CYP2D6; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Genetic Variation; Genotype; Humans; Phenotype; Venlafaxine Hydrochloride | 2010 |
Mania possibly induced by desvenlafaxine.
Topics: Antidepressive Agents; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Humans; Male; Middle Aged | 2010 |
Simultaneous quantification of venlafaxine and O-desmethylvenlafaxine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study.
Topics: Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Drug Stability; Ether; Humans; Linear Models; Male; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Venlafaxine Hydrochloride | 2010 |
Desvenlafaxine: a therapeutic option for treatment of menopausal hot flashes.
Topics: Cyclohexanols; Desvenlafaxine Succinate; Female; Hot Flashes; Humans; Menopause; Selective Serotonin Reuptake Inhibitors | 2010 |
Correction of venlafaxine- and duloxetine-induced transaminase elevations with desvenlafaxine in a patient with Gilbert's syndrome.
Topics: Adult; Aminoacyltransferases; Antidepressive Agents; Cyclohexanols; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Gilbert Disease; Humans; Male; Thiophenes; Venlafaxine Hydrochloride | 2010 |
Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Cytochrome P-450 CYP2D6; Databases, Factual; Desvenlafaxine Succinate; Drug Interactions; Female; Forensic Pathology; Gas Chromatography-Mass Spectrometry; Genotype; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2011 |
Stereoselective determination of venlafaxine and its three demethylated metabolites in human plasma and whole blood by liquid chromatography with electrospray tandem mass spectrometric detection and solid phase extraction.
Topics: Chromatography, Liquid; Cyclohexanols; Desvenlafaxine Succinate; Drug Stability; Humans; Selective Serotonin Reuptake Inhibitors; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization; Stereoisomerism; Venlafaxine Hydrochloride | 2010 |
Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder.
Topics: Adolescent; Adult; Age Factors; Aged; Ambulatory Care; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sex Factors; Statistics as Topic; Treatment Outcome; Young Adult | 2010 |
Antidepressant "treatment".
Topics: Citalopram; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Middle Aged; Neurotransmitter Uptake Inhibitors; Randomized Controlled Trials as Topic; Research Design; Selective Serotonin Reuptake Inhibitors | 2010 |
Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Humans; Middle Aged; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Risk; Suicide; Suicide, Attempted; Young Adult | 2010 |
A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Data Collection; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Fatigue; Fluvoxamine; Humans; Internet; Lethargy; Mianserin; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sleep Stages; Thiophenes; Venlafaxine Hydrochloride | 2011 |
HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Young Adult | 2010 |
Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression.
Topics: Adult; Amisulpride; Antidepressive Agents; Breast Feeding; Cyclohexanols; Depressive Disorder; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Lactation; Milk, Human; Sulpiride | 2010 |
Estimation of desvenlafaxine transfer into milk and infant exposure during its use in lactating women with postnatal depression.
Topics: Adult; Antidepressive Agents; Breast Feeding; Cyclohexanols; Depression, Postpartum; Desvenlafaxine Succinate; Female; Humans; Infant; Infant, Newborn; Lactation; Male; Milk, Human | 2011 |
Tolerance to desvenlafaxine in rapid metabolizing depressed patients.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Depressive Disorder, Major; Desvenlafaxine Succinate; Drug Tolerance; Female; Genotype; Humans; Male; Middle Aged; Polymorphism, Genetic | 2011 |
Quantification of antidepressants and antipsychotics in human serum by precipitation and ultra high pressure liquid chromatography-tandem mass spectrometry.
Topics: Antidepressive Agents; Antipsychotic Agents; Chemical Precipitation; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Dibenzothiazepines; Humans; Methanol; Mianserin; Mirtazapine; Piperazines; Quetiapine Fumarate; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles; Venlafaxine Hydrochloride; Zinc Sulfate | 2011 |
IFN-gamma reduction by tricyclic antidepressants.
Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Cytokines; Depressive Disorder; Desipramine; Desvenlafaxine Succinate; Female; Humans; Imipramine; In Vitro Techniques; Interferon-gamma; Male; Nortriptyline; Venlafaxine Hydrochloride | 2010 |
Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Blood-Brain Barrier; Brain; Caco-2 Cells; Cell Membrane Permeability; Cells, Cultured; Cyclohexanols; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Drug Interactions; Endothelial Cells; Enzyme Inhibitors; Fluorescent Dyes; Humans; Intestinal Absorption; Neoplasm Proteins; Rhodamine 123; Rifampin; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2011 |
Antidepressant-mediated gastroesophageal reflux disease.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Desvenlafaxine Succinate; Female; Gastroesophageal Reflux; Humans; Middle Aged | 2011 |
Inhibitory effects of desvenlafaxine on gastric slow waves, antral contractions, and gastric accommodation mediated via the sympathetic mechanism in dogs.
Topics: Animals; Antidepressive Agents; Cyclohexanols; Desvenlafaxine Succinate; Dogs; Gastric Emptying; Gastrointestinal Motility; Neurotransmitter Uptake Inhibitors; Pyloric Antrum; Stomach | 2011 |
A simple HPLC method for the simultaneous determination of venlafaxine and its major metabolite O-desmethylvenlafaxine in human serum.
Topics: Antidepressive Agents; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Humans; Solid Phase Extraction; Venlafaxine Hydrochloride | 2011 |
Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
Topics: Antidepressive Agents, Second-Generation; Chromatography, Liquid; Cyclohexanols; Cytochrome P-450 CYP2D6; Desvenlafaxine Succinate; Forensic Toxicology; Genotype; Humans; Stereoisomerism; Tandem Mass Spectrometry; Venlafaxine Hydrochloride | 2012 |
Occurrence and removal of lidocaine, tramadol, venlafaxine, and their metabolites in German wastewater treatment plants.
Topics: Absorption; Analgesics, Opioid; Anesthetics, Local; Antidepressive Agents, Second-Generation; Cyclohexanols; Desvenlafaxine Succinate; Gas Chromatography-Mass Spectrometry; Germany; Lidocaine; Limit of Detection; Sewage; Solid Phase Extraction; Solubility; Sonication; Tramadol; Venlafaxine Hydrochloride; Waste Disposal, Fluid; Water Pollutants, Chemical; Water Pollution, Chemical | 2012 |
Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
Topics: Animals; Antidepressive Agents; Brain; Cyclohexanols; Desvenlafaxine Succinate; Dopamine; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Hypothalamus; Immobility Response, Tonic; Male; Microdialysis; Motor Activity; Neurotransmitter Uptake Inhibitors; Norepinephrine; Prodrugs; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin | 2011 |
Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cardiomyopathies; Cyclohexanols; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Desvenlafaxine Succinate; Drug Overdose; Female; Gene Deletion; Half-Life; Heart Failure; Humans; Milrinone; Norepinephrine; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2011 |
Occurrence of Tako-Tsubo cardiomyopathy in association with ingestion of serotonin/noradrenaline reuptake inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Cyclohexanols; Desvenlafaxine Succinate; Drug Overdose; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Normetanephrine; Peptide Fragments; Selective Serotonin Reuptake Inhibitors; Takotsubo Cardiomyopathy; Venlafaxine Hydrochloride | 2012 |
The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cyclohexanols; Desvenlafaxine Succinate; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Retrospective Studies; Sex Characteristics; Smoking; Venlafaxine Hydrochloride | 2012 |
Field and laboratory studies of the fate and enantiomeric enrichment of venlafaxine and O-desmethylvenlafaxine under aerobic and anaerobic conditions.
Topics: Aerobiosis; Biodegradation, Environmental; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Laboratories; Oxidation-Reduction; Sewage; Stereoisomerism; Tandem Mass Spectrometry; Venlafaxine Hydrochloride; Waste Disposal, Fluid; Water Pollutants, Chemical | 2012 |
Impact of wastewater treatment plant discharge of lidocaine, tramadol, venlafaxine and their metabolites on the quality of surface waters and groundwater.
Topics: Cyclohexanols; Desvenlafaxine Succinate; Environmental Monitoring; Groundwater; Lidocaine; Rivers; Tramadol; Venlafaxine Hydrochloride; Waste Disposal, Fluid; Water Pollutants, Chemical; Water Pollution, Chemical | 2012 |
Desvenlafaxine-induced myositis with positive medication rechallenge.
Topics: Antidepressive Agents; Arm; Cyclohexanols; Desvenlafaxine Succinate; Female; Humans; Myositis; Young Adult | 2012 |
Metabolites: novel therapeutics or "me-too" drugs? Using desvenlafaxine as an example.
Topics: Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclohexanols; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Desvenlafaxine Succinate; Humans; Meta-Analysis as Topic | 2012 |
An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator.
Topics: Adult; Aged; Antidepressive Agents; Australia; Bayes Theorem; Cyclohexanols; Databases, Factual; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; Nausea; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2012 |
Degradation of lidocaine, tramadol, venlafaxine and the metabolites O-desmethyltramadol and O-desmethylvenlafaxine in surface waters.
Topics: Cyclohexanols; Desvenlafaxine Succinate; Hydrogen-Ion Concentration; Lidocaine; Models, Chemical; Photochemical Processes; Rivers; Sunlight; Tramadol; Venlafaxine Hydrochloride; Water Pollutants, Chemical | 2013 |
Liquid chromatography tandem mass spectrometry method for the simultaneous stereoselective determination of venlafaxine and its major metabolite, O-desmethylvenlafaxine, in human plasma.
Topics: Acetates; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Drug Stability; Humans; Hydrogen-Ion Concentration; Least-Squares Analysis; Male; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Stereoisomerism; Tandem Mass Spectrometry; Temperature; Venlafaxine Hydrochloride | 2013 |
A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Central Nervous System Depressants; Cyclohexanols; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Desvenlafaxine Succinate; Ethanol; Forensic Toxicology; Gene Deletion; Gene Duplication; Genotype; Humans; Male; Oxycodone; Polymorphism, Single Nucleotide; Venlafaxine Hydrochloride | 2013 |
Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis.
Topics: Antidepressive Agents; Antipsychotic Agents; Case-Control Studies; Central Nervous System Stimulants; Cyclohexanols; Desvenlafaxine Succinate; Dextroamphetamine; Drug Industry; Gift Giving; Health Care Sector; Humans; Interprofessional Relations; Isoxazoles; Marketing of Health Services; Organizational Policy; Paliperidone Palmitate; Practice Patterns, Physicians'; Psychotropic Drugs; Pyrimidines; Schools, Medical; United States | 2013 |
Hollow-fiber liquid-phase microextraction and chiral LC-MS/MS analysis of venlafaxine and its metabolites in plasma.
Topics: 1-Octanol; Antidepressive Agents, Second-Generation; Calibration; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Humans; Hydrogen-Ion Concentration; Liquid Phase Microextraction; Stereoisomerism; Tandem Mass Spectrometry; Venlafaxine Hydrochloride | 2013 |
Simultaneous quantitation of venlafaxine and its main metabolite, O-desmethylvenlafaxine, in human saliva by HPLC.
Topics: Antidepressive Agents; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Female; Humans; Male; Saliva; Sensitivity and Specificity; Venlafaxine Hydrochloride | 2013 |
Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression?
Topics: Animals; Antidepressive Agents; Antioxidants; Behavior, Animal; Corticosterone; Cyclohexanols; Depression; Desvenlafaxine Succinate; Drug Therapy, Combination; Exploratory Behavior; Female; Hindlimb Suspension; Mice; Stress, Psychological; Swimming; Thioctic Acid | 2013 |
Desvenlafaxine-induced worsening of hypertension.
Topics: Antidepressive Agents; Anxiety; Cyclohexanols; Desvenlafaxine Succinate; Female; Humans; Hypertension; Middle Aged | 2013 |
Desvenlafaxine succinate ameliorates visceral hypersensitivity but delays solid gastric emptying in rats.
Topics: Acetic Acid; Administration, Oral; Adrenergic Uptake Inhibitors; Animals; Cyclohexanols; Desvenlafaxine Succinate; Disease Models, Animal; Dose-Response Relationship, Drug; Electromyography; Gastric Emptying; Gastroparesis; Hyperalgesia; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Mechanotransduction, Cellular; Norepinephrine; Pain Measurement; Pain Threshold; Pressure; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Stomach; Stomach Ulcer | 2013 |
Acute and chronic effects of desvenlafaxine on gastrointestinal transit and motility in dogs.
Topics: Animals; Antidepressive Agents; Cyclohexanols; Desvenlafaxine Succinate; Dogs; Female; Gastrointestinal Transit; Muscle Contraction; Muscle, Smooth | 2013 |
Effect of venlafaxine and desvenlafaxine on drug efflux protein expression and biodistribution in vivo.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Brain; Cyclohexanols; Desvenlafaxine Succinate; Drug Interactions; Intestinal Absorption; Intestinal Mucosa; Liver; Male; Mice; Mice, Knockout; Tissue Distribution; Topotecan; Up-Regulation; Venlafaxine Hydrochloride | 2013 |
Syndrome of inappropriate antidiuretic hormone secretion associated with desvenlafaxine.
Topics: Antidepressive Agents; Cyclohexanols; Desvenlafaxine Succinate; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Middle Aged | 2014 |
Phenolic esters of O-desmethylvenlafaxine with improved oral bioavailability and brain uptake.
Topics: Administration, Oral; Animals; Biological Availability; Brain; Cyclohexanols; Desvenlafaxine Succinate; Dogs; Esters; Prodrugs; Rats | 2013 |
The comparison of brand-name and generic formulations of venlafaxine: a therapeutic drug monitoring analysis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Desvenlafaxine Succinate; Drug Monitoring; Drugs, Generic; Female; Humans; Male; Middle Aged; Serum; Sex Characteristics; Smoking; Venlafaxine Hydrochloride; Young Adult | 2014 |
Khedzela--a new brand of desvenlafaxine.
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder; Desvenlafaxine Succinate; Humans; Neurotransmitter Uptake Inhibitors | 2014 |
Determination of venlafaxine and O-desmethylvenlafaxine in dried blood spots for TDM purposes, using LC-MS/MS.
Topics: Antidepressive Agents; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Dried Blood Spot Testing; Drug Monitoring; Humans; Sensitivity and Specificity; Tandem Mass Spectrometry; Venlafaxine Hydrochloride | 2014 |
Distribution of venlafaxine, O-desmethylvenlafaxine, and O-desmethylvenlafaxine to venlafaxine ratio in postmortem human brain tissue.
Topics: Adult; Brain Chemistry; Chromatography, Liquid; Cyclohexanols; Desvenlafaxine Succinate; Female; Humans; Male; Middle Aged; Postmortem Changes; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2014 |
Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2014 |
The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats.
Topics: Animals; Antidepressive Agents; Benzoates; Cyclohexanols; Desvenlafaxine Succinate; Dopamine; Extracellular Space; Male; Microdialysis; Norepinephrine; Piperazines; Pyridines; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Swimming | 2014 |
Desvenlafaxine may accelerate neuronal maturation in the dentate gyri of adult male rats.
Topics: Animals; Antidepressive Agents; Biomarkers; Body Weight; Cell Count; Cell Differentiation; Cyclohexanols; Dentate Gyrus; Desvenlafaxine Succinate; Male; Neurogenesis; Pyramidal Cells; Rats | 2014 |
Desvenlafaxine prevents white matter injury and improves the decreased phosphorylation of the rate-limiting enzyme of cholesterol synthesis in a chronic mouse model of depression.
Topics: Animals; Antidepressive Agents; Cholesterol; Cyclohexanols; Depression; Desvenlafaxine Succinate; Disease Models, Animal; Female; Mice; Mice, Inbred C57BL; Phosphorylation; Random Allocation; White Matter | 2014 |
But does it work in women like me?
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Female; Humans; Menopause | 2014 |
Distribution of venlafaxine and O-desmethylvenlafaxine in a fatal case.
Topics: Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Desvenlafaxine Succinate; Forensic Toxicology; Gas Chromatography-Mass Spectrometry; Humans; Male; Suicide; Tissue Distribution; Venlafaxine Hydrochloride | 2014 |
Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Desvenlafaxine Succinate; Female; Humans; Male; Middle Aged; Venlafaxine Hydrochloride | 2015 |
Effect of redox conditions on pharmaceutical loss during biological wastewater treatment using sequencing batch reactors.
Topics: Aerobiosis; Anaerobiosis; Atenolol; Biological Oxygen Demand Analysis; Bioreactors; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Nitrogen; Oxidation-Reduction; Oxygen; Pharmaceutical Preparations; Phenytoin; Sewage; Solid Phase Extraction; Sulfamethoxazole; Tandem Mass Spectrometry; Trimethoprim; Waste Disposal, Fluid; Water Pollutants, Chemical | 2015 |
In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor.
Topics: Animals; Antidepressive Agents; Binding, Competitive; CHO Cells; Cricetulus; Cyclohexanols; Depression; Desvenlafaxine Succinate; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Humans; Hypothermia; Male; Mice; Molecular Structure; Motor Activity; Neurotransmitter Uptake Inhibitors; Norepinephrine; Rats, Sprague-Dawley; Serotonin; Species Specificity | 2015 |
Desvenlafaxine reduces apoptosis in amygdala after myocardial infarction.
Topics: Amygdala; Analysis of Variance; Animals; Apoptosis; Caspase 3; Caspase 8; Cyclohexanols; Desvenlafaxine Succinate; Disease Models, Animal; In Situ Nick-End Labeling; Male; Myocardial Infarction; Neurotransmitter Uptake Inhibitors; Rats; Rats, Sprague-Dawley; Reperfusion; Statistics as Topic | 2014 |
First MEPS/HPLC assay for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in human plasma.
Topics: Calibration; Chromatography, High Pressure Liquid; Cyclohexanols; Desvenlafaxine Succinate; Humans; Limit of Detection; Reference Standards; Reproducibility of Results; Spectrometry, Fluorescence; Venlafaxine Hydrochloride | 2014 |
A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
Topics: Administration, Oral; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Menopause; Middle Aged; Postmenopause; Psychiatric Status Rating Scales; Treatment Outcome | 2015 |
[The enantioselective pharmacokinetic study of desvenlafaxine sustained release tablet in Chinese healthy male volunteers after oral administration].
Topics: Administration, Oral; Area Under Curve; Asian People; Chromatography, Liquid; Cyclohexanols; Delayed-Action Preparations; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Male; Plasma; Stereoisomerism; Tablets; Tandem Mass Spectrometry | 2015 |
Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Child; Cyclohexanols; Cytochrome P-450 CYP2D6; Desvenlafaxine Succinate; Female; Genotype; Humans; Male; Middle Aged; Paliperidone Palmitate; Predictive Value of Tests; Retrospective Studies; Risperidone; Sensitivity and Specificity; Venlafaxine Hydrochloride; Young Adult | 2016 |
Selective solid-phase extraction using molecularly imprinted polymers for analysis of venlafaxine, O-desmethylvenlafaxine, and N-desmethylvenlafaxine in plasma samples by liquid chromatography-tandem mass spectrometry.
Topics: Acrylates; Antidepressive Agents; Chromatography, High Pressure Liquid; Cyclohexanols; Depression; Desvenlafaxine Succinate; Humans; Methacrylates; Microscopy, Electron, Scanning; Molecular Imprinting; Nitriles; Polymerization; Polymers; Solid Phase Extraction; Spectroscopy, Fourier Transform Infrared; Tandem Mass Spectrometry; Toluene; Venlafaxine Hydrochloride | 2016 |
Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Databases, Factual; Desvenlafaxine Succinate; Doxepin; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Polypharmacy; Venlafaxine Hydrochloride | 2018 |
Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.
Topics: Aged; Alleles; Antidepressive Agents, Second-Generation; Cyclohexanols; Cytochrome P-450 CYP2D6; Desvenlafaxine Succinate; Drug Monitoring; Female; Genotype; Humans; Male; Middle Aged; Norway; Retrospective Studies; Venlafaxine Hydrochloride | 2019 |
Venlafaxine and desvenlafaxine to be included in the surface water Watch List.
Topics: Cyclohexanols; Cytochrome P-450 CYP2D6; Desvenlafaxine Succinate; Humans; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride; Water | 2021 |
Venlafaxine and O-desmethylvenlafaxine serum levels are positively associated with antidepressant response in elder depressed out-patients.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Desvenlafaxine Succinate; Drug Monitoring; Humans; Outpatients; Venlafaxine Hydrochloride | 2022 |